Dotarem® was first developed in 1989 with the aim of minimizing the release risk of gadolinium. It is the first macrocyclic and ionic gadolinium-based contrast agent approved in the USA.
Indications:
Nuclear magnetic resonance imaging:
- Neuroradiology: tumour of the spine and the surrounding tissues, intracranial tumours.
- Abdominal radiology: primary and secondary tumours.
- Primary tumour of the bone and soft tissues.
Presentation: Box of 1 vial of 10mL
Storage: Do not store above 30°C
